Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients78

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients24

Views

Views
September 20253
October 20253
November 20257
December 20255
January 20264
February 20260
March 20262
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil8
United States6
United Kingdom2
Argentina2
Chile1
Algeria1
Ecuador1
Singapore1
Venezuela1
South Africa1
 

Top cities views

Views
Dallas2
Los Angeles2
São Paulo2
Buenos Aires2
Ashburn1
Brasília1
Campinas1
Cuenca1
Mauá1
Pretoria1